Did you mean iodide i 10?
Displaying drugs 3376 - 3400 of 3712 in total
Peresolimab
Peresolimab is under investigation in clinical trial NCT04634253 (A Study of LY3462817 in Participants With Rheumatoid Arthritis).
Investigational
Posdinemab
Posdinemab is under investigation in clinical trial NCT04619420 (A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease).
Investigational
Cyclo(his-pro)
Experimental
Torapsel
Torapsel has been used in trials studying the prevention of Ischemia Reperfusion Injury.
Investigational
Apitegromab
Apitegromab is under investigation in clinical trial NCT03921528 (An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy).
Investigational
Rinucumab
Rinucumab is under investigation in clinical trial NCT02418754 (Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-related Macular Degeneration (AMD)).
Investigational
Ocaratuzumab
Ocaratuzumab is a humanized monoclonal antibody directed against CD20. It is being investigated for cancers and autoimmune disorders.
Investigational
Briquilimab
Briquilimab is a humanized aglycosylated IgG1 kappa monoclonal antibody targeting CD117 (cKit).
Investigational
Peptide YY (1-36)
Investigational
scAAV9.U7.ACCA
scAAV9.U7.ACCA is a non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon 2 in the human DMD gene under the control of U7 small nuclear non-coding RNA. Developed by Nationwide Children’s Hospital, it is being investigated for the treatment of Duchenne muscular dystrophy.
Investigational
Litifilimab
Litifilimab is under investigation in clinical trial NCT05531565 (A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) And/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory And/or Intolerant to Antimalarial Therapy).
Investigational
Livmoniplimab
Livmoniplimab is under investigation in clinical trial NCT06109272 (A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)).
Investigational
Cedirogant
Cedirogant is under investigation in clinical trial NCT05044234 (A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis).
Investigational
Displaying drugs 3376 - 3400 of 3712 in total